Enfortumab Vedotin for Adenoid Cystic Carcinoma

Recruiting in Palo Alto (17 mi)

+6 other locations

Overseen byAlan Ho, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Research Team

Alan Ho, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This clinical trial is for individuals with adenoid cystic carcinoma, a type of cancer that can occur in various parts of the body. Participants should have this specific diagnosis to be eligible.

Inclusion Criteria

I have or can provide tumor tissue samples for study.

Participants must be willing to sign the written informed consent form

Screening laboratory values must meet specific criteria including Neutrophils, Platelets, Hemoglobin, AST, ALT, Total Bilirubin, Serum creatinine, and Creatinine clearance

See 11 more

Exclusion Criteria

I have brain metastasis that has not been treated.

I haven't had cancer treatment in the last 4 weeks.

I haven't had serious heart issues like heart failure, unstable angina, heart attack, or dangerous arrhythmias in the last 6 months.

See 9 more

Treatment Details

Interventions

Enfortumab Vedotin (Antibody-drug Conjugate)

Trial OverviewThe study is testing enfortumab vedotin's effectiveness and safety as a treatment option for those suffering from adenoid cystic carcinoma.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Enfortumab VedotinExperimental Treatment1 Intervention

Participants are treated with enfortumab vedotin at the FDA-approved dose and schedule of intravenously on Days 1, 8 and 15 of a 28-day cycle.